Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We are pioneering a biotech revolution to create a range of next generation products that improve human health and wellbeing, increase environmental sustainability, and advance solutions that address the challenges of the future – from climate change and aging associated illnesses to food scarcity, animal cruelty and beyond.
From one core technology, we are developing next generation cell-based products across a range of fields and industries from pharma to food tech and beyond.
We are developing platforms to expand high-quality human, plant and animal cells at large scale and low costs. This has a potential impact on every aspect of the life sciences. Our technology has the potential to be implemented in various industries such as pharma, food tech, agtech, biologics and beyond.
Nice DD !!! The Warrants Are For Plurinuva Not For Pluri !!! Keep The Comedy Coming !!!
Stop This Video Below At Exactly The 1 Minute Mark... To See What A Pluri Steak Looks Like !!!
Wow !!![color=red][color=red][/color][/color]
Tweet Tweet[color=red][/color]
https://twitter.com/Pluribiotech
We Should Know After The Close On The TASE Tomorrow,??? If Tnuva Bought The $40.00 Plurinuva Warrants !!!
It's Coming !!! IMO....The Recent US Approval Sealed The Deal !!!
Israel to invest $18m in cultivated meat consortium
https://www.i24news.tv/en/news/israel/environment/1650349383-israel-to-invest-18m-in-cultivated-meat-consortium
My Guess Is...If They Do Not Purchase The Warrants By Next Tuesday, Then One Could Make The Argument That Tnuva Is Not Super Excited About Plurinuva's Product Going Forward. On The Flip Side, If They Do Buy Them One Could Expect A Possible IPO In The Future.
On August 23, 2022, the First Warrant was extended for an additional 90-day period, so that the exercise period will end on November 22, 2022.
From: 10-Q
The first warrant, or the First Warrant, issued to Tnuva permits Tnuva to purchase up to 125,000 ordinary shares of Plurinuva at an exercise price of $40.00 per share and has a term commencing on the Closing Date and ending at the earlier of (i) six months from the Closing Date, (ii) immediately prior to and subject to the consummation of an initial public offering or acquisition of Plurinuva or (iii) the consummation of a financing round with a non-affiliated investor. In addition, on the six month anniversary of the Closing Date, and provided that the First Warrant has not expired, Plurinuva shall issue to Tnuva a second warrant, or the Second Warrant, which will permit Tnuva to purchase up to a number of ordinary shares of Plurinuva, or the then most senior securities issued by Plurinuva, in consideration for such amount equal to 200% of the remaining balance of the aggregate purchase price of the First Warrant, provided that Tnuva exercises at least 62,500 ordinary shares at a price per share of $40.00, or $2,500,000 in the aggregate, of the First Warrant. The Second Warrant’s exercise price per share equals $76.00. The Second Warrant has a term commencing on the six months anniversary of the Closing Date and ending at the earlier of (i) six months from its issuance, (ii) immediately prior to and subject to the consummation of an initial public offering or acquisition of Plurinuva or (iii) the consummation of a financing round with a non-affiliated investor. On August 23, 2022, the First Warrant was extended for an additional 90-day period, so that the exercise period will end on November 22, 2022.
Breaking: Upside Foods Earns FDA GRAS Approval for Its Cultivated Meat in ‘Watershed Moment’
https://www.greenqueen.com.hk/upside-foods-fda-gras-approval-cultivated-meat/
Lab-Grown Meat Gets FDA Approval for the First Time Ever
https://www.msn.com/en-us/news/technology/lab-grown-meat-gets-fda-approval-for-the-first-time-ever/ar-AA14c374
LIOR RAVIV Chief Technology Officer at Pluri, Israel
https://informaconnect.com/challenges-and-opportunities-for-mscs/speakers/lior-raviv/
NITSAN HALVEY Chief Medical Officer at Pluri, Israel
https://informaconnect.com/challenges-and-opportunities-for-mscs/speakers/nitsan-halvey/
I See BARDA Day Is This Week Too !!!
https://www.medicalcountermeasures.gov/barda/barda-industry-day-2022/#speakers
You Never Did....Nor Will You Ever... Have A Clue !!!
Would YOU Be The The First Human Volunteer For Radiation Studies !!! HOPE SO !!!
Would Be The The First Human Volunteer For Radiation Studies !!! HOPE SO !!!
FULL TEXT OF STUDY
https://www.mdpi.com/2073-4425/13/10/1756/htm
Is The Department Of Defense Scambling To Approve PLX-R18 ???
They Are Wrapping Up Studies !!!
Received: 2 September 2022 / Revised: 22 September 2022 / Accepted: 23 September 2022 / Published: 28 September 2022[/b
https://www.mdpi.com/2073-4425/13/10/1756
Once Again, I Would Like To Thank The Many Uninformed Investors Who Sold And Allowed The Astute DD Investors To Buy As Many Inexpensive Shares As They Wanted !!!
It's Going To Be A November To Remember !!!
GIDDY-UP !!![/b]
FYI:
Tnuva Has Until November 22nd To Buy The Plurinuva Warrant Shares At $ 40.00 Per Share !!!
NO.....IMO...WONDERFUL NEWS COMING !!!
https://legacy.pluristem.com/news-and-events/jefferies-london-healthcare-conference-2022/
Pluri operates a state-of-the-art good manufacturing practice (GMP) manufacturing facility; maintains an IP portfolio of over 130 active, granted patents; and is:
Cultivating a Fast-Growing Network of Global Partnerships that expand the impact of its technology to industries that require efficient mass cell production, such as pharma, food-tech and biologics.
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
https://legacy.pluristem.com/wp-content/uploads/2021/06/Pluri_wins_BioTech_Breakthrough_-FINAL_isa.pdf
IMO...PLURI IS GROWING THE RED BLOOD CELLS IN THEIR BIOREACTORS!
Highly Likely This Is PLURI !!! IMO...The Odds Of It Being Pluri Is 90 % !!!
INCREDIBLE !!! FIRST IN THE WORLD !!![color=red][/color]
Lab-grown red blood cells transfused into people in first trial -NHS
[/b
https://www.jpost.com/breaking-news/article-721676
Highly Likely This Is PLURI !!! IMO...The Odds Of It Being Pluri Is 90 % !!!
INCREDIBLE !!! FIRST IN THE WORLD !!![color=red][/color]
Lab-grown red blood cells transfused into people in first trial -NHS
[/b
https://www.jpost.com/breaking-news/article-721676
Pre-Administration of PLX-R18 Cells Protects Mice from Radiation-Induced Hematopoietic Failure and Lethality
Flt3L has been reported as an efficacy biomarker of bone marrow damage and SAA and PCT was reported as marker of sepsis following organ damage [37,38]. All these protein levels are significantly increased after radiation with time as expected, however, PLX-R18 pre-treatment lowered these protein levels and brought them back to near basal levels. [b[color=red]]This suggests that part of the radioprotection afforded by PLX-R18 is the result of reducing bone marrow damage and sepsis following radiation exposure in mice.[/color]
The protection afforded by PLX-R18 to the hematopoietic system after irradiation was evidenced by the accelerated recovery of white blood cell, lymphocyte, neutrophil, and platelet counts (most notably on Day 21 after irradiation), compared to vehicle-treated animals as observed previously by us with other promising countermeasures [32,33,43]. Although PLX-R18 treatment was unable to restore sternal megakaryocyte counts and clonogenic potential of femoral bone marrow cells to the levels observed in non-irradiated animals, both parameters were significantly higher by Day 30 after irradiation in PLX-R18-treated animals than in PlasmaLyte-treated counterparts, demonstrating the ability of PLX-R18 to aid in the recovery of femoral and sternal bone marrow stem cells. Furthermore, femoral bone marrow clonogenic potential assessed on Day 45 in the PLX-R18-treated group demonstrated continued improvement of this parameter.
Conclusions
In conclusion[color=red][/color], our data show the systemic effect of PLX-R18 pre-treatment protects mice from radiation-induced bone marrow aplasia and rescues them from lethality. In addition to attenuating hematopoietic and immune system dysfunction, PLX-R18 also reduces vascular oxidative stress and pro-inflammatory cytokines/chemokines and growth factors, inhibited the expression of pAKT. Further studies need to be conducted to explore the detailed mechanism and cascade of events contributing to the radioprotection afforded by PLX-R18 cells. Evaluating the efficacy of this countermeasure on female mice would also add value to the studies that could be included for an FDA IND application. Further development of PLX-R18 as a radioprotectant could have a significant impact on radiation biology, radiation oncology, and military medicine.
https://www.mdpi.com/2073-4425/13/10/1756/htm
64th ASH MEETING Monday, December 12, 2022, 6:00 PM-8:00 PM
#4686 PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
Among patients who received blood transfusions at any time during follow up, a meaningful reduction in the mean number of transfused units per month, for both PLT and RBC transfusions, was observed as early as 3 months following PLX-R18 treatment and lasted throughout the 12-month follow up period. For PLT, the mean monthly number of transfused units dropped from 5.09 at baseline to 0.55 at 12 months (p<0.05); for RBC, from 2.91 at baseline to 0.00 at 12 months (p=0.0005).
Conclusion: PLX-R18 therapy appears to be safe and well tolerated and shows promise in improving incomplete hematopoietic recovery after HCT. Further clinical studies are warranted to optimize the efficacy of PLX-R18 in treatment of cytopenia in the post-HCT setting and expand the potential to other marrow failure disorders as well as cytopenia associated with certain treatment modalities such as CAR-T therapy.
https://ash.confex.com/ash/2022/webprogram/Paper169266.html
November 9th & 10th !!! Giddy-Up !!!
https://legacy.pluristem.com/news-and-events/mixiii-biomed/